Good MorningThe equities market ended a strong week on an up note despite growing concerns about the COVID-19 pandemic. The number of new cases continues to set new records even as the broad market S&P 500 tries to set a new all-time closing high. The risk for markets is another shutdown. Although, President-Elect Joe Biden’s advisors backed off the suggestion to close the economy for 6 weeks the threat remains.
Next week could be challenging for the market. It is the mid-month data dump and includes eight major economic reports. Among them are Retail Sales, Business Inventories, The Index of Leading Indicators, and a host of housing data. Strong or stronger than expected figures could send the equity market to new all-time highs despite the threat of COVID and there is every reason to think they will be.
Featured: Elon’s big $266,000 per second purchase (Ad) 
|
Consumer Staples | |
When we consider which stocks have benefitted from market trends caused by the pandemic, usually the first ones that come to mind are cloud-based software companies, e-commerce companies, and any of the “stay-at-home” stocks. On the other hand, the brick-and-mortar retail industry has ... Read the Full Story |
|
From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
|
Markets | |
There are several characteristics in a high-quality growth stock that investors should always look for before adding shares to their portfolio. These include things such as strong sales growth, justifiable valuations, and a large target market that is poised to grow for many years to come. One com... Read the Full Story |
|
Retail/Wholesale | |
It's been a tough year for the restaurant industry. Most companies have struggled to put food on the table amid pandemic-led shutdowns and restrictions. There have however been a handful of standout performers that have managed to not just survive but produce some impressive performances despite t... Read the Full Story |
|
From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
|
Retail/Wholesale | | A Buying Op In Advanced Auto Parts
It’s been a full quarter since I last reviewed Advanced Auto Parts (NYSE:AAP) and the situation is only more attractive. At the time, I saw the stock on the verge of a breakout and urged investors to wait for a pullback before buying. While the fundamental ... Read the Full Story |
|
Markets | |
There's a school of thought that says job cuts are good for a company's share price because it demonstrates that the company is willing to make the “tough calls” to improve the bottom line. If that's the case, then AT&T (NYSE:T) should be in line for some big gains of its own as th... Read the Full Story |
|
From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
|
Consumer Staples | | Food and beverage maker Campbell Soup Company (NYSE: CPB) shares have been in decline since peaking out at height of the pandemic as the food stockpiling phenomenon surged demand. Shares appear to be setting up for a breakdown underperforming the benchmark S&P 500 index (NYSEARCA: SPY). The adve... Read the Full Story |
|
Consumer Staples | | If It’s A Rotation They Want, Here’s Where The Value Is
The new buzzword on Wall Street is rotation, rotation, rotation. The market (at least in the minds of the mainstream media) is rotating out of growth and big-tech into value. Oddly enough, this is something I’ve been saying f... Read the Full Story |
|
Markets | | A Great Company But Rockwell Automation Is No Value
The stock market has entered a great rotation from growth to value and in that light, Rockwell Automation (NYSE:ROK) is a sell. Trading between 25X and 30X forward earnings it’s highly valued relative to the broad market making it a target f... Read the Full Story |
|
Markets | |
It seems like things are moving faster than ever in financial markets. After equity markets made a huge move up last week, we received even more bullish news that sent stocks soaring to reach new all-time highs during Monday’s trading session. Pfizer (NYSE:PFE) announced that early data from... Read the Full Story |
|
Auto/Tires/Trucks | | Workhorse Group Is About To Melt-Up
The Biden victory is a positive for the EV industry. His renewables-friendly platform will help not only the Workhorse Group but the entire EV market. Within that sphere, however, Workhorse Group is emerging as a leader not only in EV but in a very lucrative nich... Read the Full Story |
|
The Early Bird Stock Of The Day Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. | | View Today's Stock Pick |
|
